PIPELINE
Global Drug Pipeline
Tracking 10 active programs across 8 companies
STAGE DISTRIBUTION
2
2
2
3
1
Pre-clinical (2)
Phase 1 (2)
Phase 1/2 (2)
Phase 2 (3)
Approved (1)
Stage
Region
Therapeutic Area
Showing 10 of 10 programs
| Drug Name | Company | Indication | Phase | Status | Next Catalyst |
|---|---|---|---|---|---|
| Radspherin | Oncoinvent AS | Peritoneal carcinomatosis | Phase 2 | Active | Ph2 data H2 2026 |
| RAD-01 | Oncoinvent AS | Ovarian cancer | Phase 1 | Enrolling | IND filing Q3 2026 |
| VB10.16 | Nykode Therapeutics | HPV-related cancers | Phase 2 | Active | Ph2 interim Q4 2026 |
| VB10.NEO | Nykode Therapeutics | Melanoma | Phase 1/2 | Active | Combination data 2027 |
| Fimaporfin | PCI Biotech | Bile duct cancer | Phase 2 | Active | Ph2 results Q1 2027 |
| Hexvix | Photocure ASA | Bladder cancer | Approved | Marketed | Market expansion ongoing |
| LTX-315 | Lytix Biopharma | Solid tumours | Phase 1/2 | Active | Combination study 2026 |
| CAD-001 | Caedo Oncology | Solid tumours | Pre-clinical | IND-enabling | IND-enabling 2027 |
| DoMore-v1 | DoMore Diagnostics | Colorectal cancer | Pre-clinical | Validation | Clinical validation 2027 |
| ZEL-101 | Zelluna Immunotherapy | Solid tumours | Phase 1 | Enrolling | Ph1 enrollment H1 2026 |
